Mohammed, W., Alwash, S. (2021). Rate of Prescribing Statins for Primary Prevention of Atherosclerotic Cardiovascular Disease in Diabetic Patients. Alustath, 21(2), 226-235. doi: 10.52573/ipmj.2021.174634
Wathiq Kh. Mohammed; Sarah J. Alwash. "Rate of Prescribing Statins for Primary Prevention of Atherosclerotic Cardiovascular Disease in Diabetic Patients". Alustath, 21, 2, 2021, 226-235. doi: 10.52573/ipmj.2021.174634
Mohammed, W., Alwash, S. (2021). 'Rate of Prescribing Statins for Primary Prevention of Atherosclerotic Cardiovascular Disease in Diabetic Patients', Alustath, 21(2), pp. 226-235. doi: 10.52573/ipmj.2021.174634
Mohammed, W., Alwash, S. Rate of Prescribing Statins for Primary Prevention of Atherosclerotic Cardiovascular Disease in Diabetic Patients. Alustath, 2021; 21(2): 226-235. doi: 10.52573/ipmj.2021.174634

Rate of Prescribing Statins for Primary Prevention of Atherosclerotic Cardiovascular Disease in Diabetic Patients

Iraqi Postgraduate Medical Journal
Article 15, Volume 21, Issue 2, April 2022, Pages 226-235    PDF (296.33 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2021.174634
Authors
Wathiq Kh. Mohammed1; Sarah J. Alwash2
1Internal Medicine Specialist, Al-Suwairah General Hospital, Wasit, Iraq
2Family Medicine Specialist, Alkarkh Primary Healthcare Sector, Baghdad, Iraq
Abstract
BACKGROUND:
Cardiovascular diseases are the major contributor to morbidity and mortality in patients with diabetes. Dyslipidemia, a com­mon condition coexisting with type 2 diabetes, is a major cause of atherosclerosis and a risk factor for cardiovascular disease. Statin therapy plays an important role in the primary and secondary prevention of cardiovascular events in populations at elevated risk.
OBJECTIVE:
This study aims to examine the extent to which statins are used for primary prevention of atherosclerotic cardiovascular disease by diabetic patients, to identify gaps between guidelines and current daily practice, and to offer rational approach toward enhancing guideline adherence and improving quality of care.
MATERIALS AND METHOD:
A cross sectional study conducted from April 2019 to May 2020. Participants took part in a face to face personal interview in the outpatient clinic of Alsuwairah General Hospital. Patients included were those with type 1 or type 2 diabetes mellitus, aged 40-75 years, without a history of atherosclerotic cardiovascular disease.
RESULTS:
We included a total of 236 patients with diabetes mellitus, more than 2 thirds of them were ≥50 years of age. The majority (64.8%) were females. Patients with type 2 diabetes constitute 97.5% of                     the sample. Eighty six percent of patients have had diabetes for ≥2 years. Only 35 participants (14.8%) were on statin therapy. Among statin users, 62.9% have been doing so for less than 2 years. Use of statins was slightly more frequent in women than in men and it increases consistently with age; however, statistically non-significant. There was a significant association between statin prescription and increased duration of diabetes (P value 0.010).
CONCLUSION:
Statin prescription for primary prevention of ASCVD in diabetic patients is suboptimal. This finding underscores a major gap in addressing public health and cardiovascular disease burden in                              a population considered to be at high risk, and highlights an urgent need for optimising statin therapy and global risk factor control in diabetic patients without a known atherosclerotic cardiovascular disease.
 
Keywords
Diabetes Mellitus; Statin; Cardiovascular disease; Primary prevention
References
REFERENCES:

  1. Ueda P, Lung TW, Clarke P, Danaei G. Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.Br J Gen Pract [Internet]. 2017 Sep [cited 2020 ; 67:e598-e608. Availablefrom:https://bjgp.org/content/67/662/e598.
  2. Elnaem MH, Mohamed MH, Huri HZ, Azarisman SM, Elkalmi RM. Statin therapy prescribing for patients with type 2 diabetes mellitus: A review of current evidence and challenges. J Pharm Bioall Sci 2017; 9: 80-87.
  3. American Diabetes Association. Standards of medical care in diabetes-2016: Introduction. Diabetes Care [Internet]. 2016 Jan [cited 2020 Sep 22]; 39(Suppl. 1): S1–S2. Available from: https://care.diabetesjournals.org/content/39/Supplement_1/S1
  4. Kim BK, Kim HC, Ha KH, Kim DJ. Application of New Cholesterol Guidelines to the Korean Adult Diabetic Patients. J Korean Med Sci 2015; 30: 1612-17
  5. Amen SO, Baban ST, Yousif SH, Hawez AH, Baban ZT, Jalal DM. Prevalence of the most frequent risk factors in Iraqi patients with acute myocardial infarction. Med J Babylon 2020; 17: 6-18.
  6. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374: 2021-31.
  7. Mula-Abed WA, Chilmeran SK. Prevalence of dyslipidemia in the Iraqi adult population. Saudi Me J 2007; 28: 1868-74.
  8. Al Rasadi K, Almahmeed W, AlHabib KF, Abifadel M, Farhan HA, Alsifri S, et al. Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis. 2016; 252:182-87.
  9. Akhabue E, Rittner SS, Carroll JE, Crawford PM, Dant L, Laws R, et al. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers. J Am Heart Assoc [Internet]. 2017 Jul [cited 2020; 6: [11pp.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586289/
10. Koo BK.  Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. Diabetes Metab J 2014;38:32-34.

11. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. BMJ Open [Internet]. 2019 [cited 2020; 9:12. Available from: https://bmjopen.bmj.com/content/9/4/e023085

12. Mortensen MB, Kulenovic I, Falk E. Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction. Cardiovasc Diabetol [Internet]. 2016 May [cited 2020 ;15:8pp.AvailablefromPMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882784/

13. Jones NR, Fischbacher CM, Guthrie B, Leese G, Lindsay RS, et al. Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006–2008. Diabet Med 2014;31:640-46.

14. Johansen ME, Green LA. Cardiovascular Risk and Statin Use in the United States.  Ann Fam Med 2014;12:215-23.

15. Stone NJ, Robinson JG, Lichtenstein AH, Merz NB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guidelineon the treatment of blood cholesterol to reduce atherosclerotic cardiovascularrisk in adults: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines. Circulation 2014; 129: S1–S45.

16. American Diabetes Association. Standards of medical care in diabetes-2017: Cardiovascular Disease and Risk Management. Diabetes Care [Internet]. 2017 Jan [cited 2020 Sep 22]; 40(Suppl. 1):S75–S87. Available from: https://care.diabetesjournals.org/content/40/Supplement_1/S75.

17. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

 

18. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. London: NICE; 2014. [cited 2020 Sep 29]. Available from: https://www.nice.org.uk/guidance/cg181.

19. Mansour A, Al Douri F. Diabetes in Iraq: Facing the Epidemic. A systematic Review. Wulfenia 2015; 22:258-73.

20. Mansour  A, Ajeel N.  Atherosclerotic cardiovascular disease among patients with type 2 diabetes in Basrah. World J Diabetes 2013;4: 82-87.

21. Collins R, Reith C, Emberson J,Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61.

22. Colhoun HM, Betteridge DJ, Durrington PN,  Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364: 685-96.

23. Murphy C, Bennett K, Fahey T, Shelley E, Graham I, Kenny RA. Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). BMJ Open [Internet]. 2015[cited 2020;5:9. Available from: https://bmjopen.bmj.com/content/5/7/e008017.long

24. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ,  et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008; 359: 2195-207.

25. Bruckert E, Ferrières J. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice. Arch Cardiovasc Dis 2014 Mar; 107:188-200.

26. Fung CSC, Wan EYF, Chan AKC, Lam CLK. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovasc Disord [Internet]. 2017 Jun [cited 2020;17:9. Available from: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-017-0599-x.

27. Garcia-Gil M, Comas-Cufí M, Blanch J, Martí R, Ponjoan A, Alves-Cabratosa L, et al. Effectiveness of statins as primary prevention in people with different cardiovascular risk: A population-based cohort study. Clin Pharmacol Ther 2018;104:719–32.

28. Demoz GT, Wahdey S, Kasahun GG, Hagazy K, Kinfe DG, Tasew H, et al. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia. BMC Res Notes [Internet]. 2019 Jul [cited 2020;12:7. Available from: https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-019-4423-9

29. Gupta R, Lodha S, Sharma KK, Sharma SK, Gupta S, Asirvatham AJ, et al. Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2. BMJ Open Diabetes Res Care [Internet]. 2016 [cited 2020; 4:7. Available from: https://drc.bmj.com/content/4/1/e000275

30. Elnaem MH, Nik Mohamed MH, Azarisman SM. Patterns of statin therapy prescribing among hospitalized patients with Type 2 diabetes mellitus in two Malaysian tertiary hospitals. Trop J Pharm Res 2017;16: 3005-11.

31. Hammad MA, Syed Sulaiman SA, Aziz NA, Mohamed Noor DA. Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. J Res Med Sci [Internet]. 2019 Feb[cited 2020;24:6.Available from: https://www.jmsjournal.net/article.asp?issn=1735-1995;year=2019;volume=24;issue=1;spage =15;epage=15;aulast=Hammad#google_vignette

32. Banks E, Crouch SR, Korda RJ, Stavreski B, Page K, Thurber KA, et al. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia. Med J Aust [Internet]. 2016 May [cited 2020;204:8. Available from: https://www.mja.com.au/journal/2016/204/8/absolute-risk-cardiovascular-disease-events-and-blood-pressure-and-lipid

33. Steen DL, Khan I, Becker L, Foody JM, Gorcyca K, Sanchez RJ, et al. Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population. Clin Cardiol. 2017; 40:155-62.

34. Ting RZ, Yang X, Yu LW, Luk AO, Kong AP, Tong PC, et al. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. Cardiovasc Diabetol [Internet]. 2010 Nov [cited 2020; 9:9 . Available from PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004819/

35. Sheppard JP, Fletcher K, McManus RJ, Mant J. Missed opportunities in prevention of cardiovascular disease in primary care: A cross-sectional study. Br J Gen Pract [Internet]. 2014 Jan [cited 2020;64:e38-e46. Available from PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876174/

36. Mottur-Pilson C, Snow V, Bartlett K. Physician Explanations for Failing to Comply with “Best Practices”. Eff Clin Pract 2001; 4: 207-13.

37. Zaidan ZJ, Hussein AM, Ahmed SM. Study of Dyslipidemia in Iraqi Hypertension Patients in Tikrit City. MLU 2020; 20: 516-21.

38. Reiner Ž, Sonicki Z, Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: The PERCRO-DOC survey. Atherosclerosis 2010; 213: 598–603.

39. Bos JM, Natsch S, van den Bemt P, Pot JL, Nagtegaal JE, Wieringa A, et al. A multifaceted intervention to reduce guideline non‑adherence among prescribing physicians in Dutch hospitals. Int J Clin Pharm 2017; 39: 1211–19.

40. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PC, et al. Why Don’t Physicians Follow Clinical Practice Guidelines? A Framework for Improvement. JAMA 1999; 28: 1458-65.

41. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes NS, Walsh BW, et al. National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines. Circulation 2005; 111: 499-510.

42. Clough JD, Martin SS, Navar AM, Lin L, Hardy NC, Rogers U, et al. Association of Primary Care Providers’ Beliefs of Statins for Primary Prevention and Statin Prescription. J Am Heart Assoc [Internet]. 2019 Feb [cited 2020;8:8. Available from PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405576/

43. Fürthauer J, Flamm M, Sönnichsen A. Patient and physician related factors of adherence to evidence based guidelines in diabetes mellitus type 2, cardiovascular disease and prevention: a cross sectional study. BMC Family Practice [Internet]. 2013 Apr [cited 2020;14:8. Available from PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623850/

 

Statistics
Article View: 114
PDF Download: 82


Journal Management System. Powered by ejournalplus.com